Given the relatively low frequency of PIK3CA mutations (10–20%) in colorectal cancer, it is unlikely that an effect on the mutated PIK3CA tumours alone could explain the large effects of aspirin on colorectal cancer incidence and mortality observed in the randomised vascular trials [10]. Here, PIK3CA is linked to colorectal cancer.